Literature DB >> 31680692

Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

.   

Abstract

Year:  2010        PMID: 31680692      PMCID: PMC6798877          DOI: 10.14745/ccdr.v36i00as2

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


× No keyword cloud information.
  67 in total

1.  Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers.

Authors:  Margaret Rennels; James King; Robert Ryall; Susan Manoff; Thomas Papa; Andrea Weddle; James Froeschle
Journal:  Pediatr Infect Dis J       Date:  2002-10       Impact factor: 2.129

2.  Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.

Authors:  Philippe De Wals; Van Hung Nguyen; Lonny J Erickson; Maryse Guay; Jean Drapeau; Jennifer St-Laurent
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

Review 3.  Thymus-independent and thymus-dependent responses to polysaccharide antigens.

Authors:  K E Stein
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.

Authors:  Caroline L Trotter; Nigel J Gay; W John Edmunds
Journal:  Am J Epidemiol       Date:  2005-07-01       Impact factor: 4.897

5.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

6.  Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.

Authors:  Q Zhang; S Choo; J Everard; R Jennings; A Finn
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.

Authors:  Philippe De Wals; Laurent Coudeville; Pierre Trottier; Catherine Chevat; Lonny J Erickson; Van Hung Nguyen
Journal:  Vaccine       Date:  2007-05-15       Impact factor: 3.641

Review 9.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

10.  Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.

Authors:  J Jaime Caro; Jörgen Möller; Denis Getsios; L Coudeville; Wissam El-Hadi; Catherine Chevat; Van Hung Nguyen; Ingrid Caro
Journal:  BMC Public Health       Date:  2007-06-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.